Lezat

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lezat

Quick Facts

Property Description
Active ingredient Levocetirizine dihydrochloride
Form Tablet, Oral solution
Pharmacological class H1-Receptor Antagonist
Common use Relief of allergy symptoms
Origin Synthetic, Second-Generation

What Type of Medicine is Lezat?

Lezat is a medication whose active component is Levocetirizine dihydrochloride, and it is formally classified as a Histamine-H1 Receptor Antagonist. This synthetic compound is categorized as a second-generation antihistamine, belonging to the piperazine derivative class, specifically developed to address symptoms related to allergic reactions. The classification is clinically recognized for offering a more selective therapeutic action compared to earlier agents, focusing primarily on the periphery of the body. The medicine's active ingredient is commonly available in both prescription and over-the-counter settings, depending on the regulatory region and strength.

Levocetirizine: A Selective H1-Receptor Antagonist

The pharmacological action of Lezat is defined by its core ingredient, Levocetirizine, which functions as a potent selective peripheral H1-receptor antagonist. This mechanism is characterized by the specific targeting of histamine receptors. The compound is notably the active R-enantiomer of its predecessor, Cetirizine, a feature that distinguishes it chemically and contributes to its efficiency by isolating the most therapeutically effective form of the substance. By blocking the H1-receptors, the medication helps to prevent the cascade of events that leads to irritation and inflammation from common allergic triggers.

General Purpose and Available Forms

The general purpose of Lezat is to provide reliable relief from symptoms associated with allergic conditions by quieting the body's overreaction to allergens. This makes it suitable for neutral use scenarios, such as when temporary, bothersome symptoms like itching, sneezing, or increased nasal discharge occur. Lezat is a single active ingredient preparation formulated for oral administration and is typically supplied in two main high-level dosage forms: the solid tablet for ingestion and the oral solution, which utilizes an aqueous solvent system and pharmaceutical excipients.

What side effects are possible with Lezat?

Possible Side Effects and Safety Information

The established safety profile for Lezat, which contains levocetirizine, classifies possible effects based on their frequency as documented in regulatory sources.

Adverse reactions classified as Common, occurring in at least 1 out of 100 patients, primarily involve the Nervous and Respiratory systems. These reactions include somnolence (sleepiness), fatigue, dry mouth, nasopharyngitis, and pharyngitis. Effects classified as Uncommon (ge 1/1,000 to < 1/100) include asthenia and abdominal pain.

Serious Adverse Reactions and Systemic Observations

The official safety documents note the possibility of rare but clinically significant reactions. These include severe hypersensitivity reactions, such as anaphylaxis and angioneurotic oedema. The medication has been associated with urinary retention and, in rare instances, convulsions or seizure aggravation, requiring caution in patients with a history of epilepsy.

Post-marketing reports also classify events with a Not Known frequency across numerous System-Organ Classes, including Psychiatric Disorders (aggression, depression, suicidal ideation) and Cardiac Disorders (palpitations, tachycardia).

Population-Specific Safety Constraints

Specific limitations exist for populations with compromised renal function. Lezat is formally contraindicated in patients with end-stage renal disease (creatinine clearance <10 mL/min) and in children aged 6 months to 11 years with any degree of impaired renal function. Caution is advised in older adults due to the increased likelihood of age-related renal function decline.

Furthermore, concurrent use with alcohol or other Central Nervous System (CNS) depressants may cause an additional reduction in alertness. A time-related safety pattern noted is the risk of severe pruritus (intense itching) reported after stopping the medication following long-term daily use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Lezat, whose active ingredient is Levocetirizine dihydrochloride, is documented based on the clinical manifestations and the procedures mandated by regulatory authorities.

Feature Official Regulatory Statement
Documented Manifestations Symptoms observed are primarily related to Central Nervous System (CNS) effects. In adults, the main presentation is drowsiness (somnolence). In children, the initial signs of overdose may include agitation and restlessness before the onset of drowsiness.
Emergency Actions Required Seek emergency medical attention immediately, or contact a poison control helpline.
Urgent Help Triggers Urgent medical help is required if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened, as stated in the official guidance for overdose situations.
Antidote Availability No known specific antidote to Levocetirizine is available.
Management Procedures Management should be restricted to symptomatic and supportive treatment. Gastric lavage should be considered following a short-term ingestion. The compound is not effectively removed from the body by haemodialysis (dialysis is ineffective).

This structure defines the expected clinical course of an overdose, centered on CNS depression, and outlines the required emergency actions that must be taken, particularly when severe, acute symptoms are present.

Therapeutic Uses of Lezat

What Lezat Treats: Main Uses and Benefits

Lezat is commonly used across domains where additional symptomatic support is needed, to help address symptoms related to heightened physiological activity. The medication may be relevant in conditions presenting with systemic or localized discomfort, and contributes to easing the overall symptom load. Its therapeutic use is associated with specific allergic conditions.

The medication is generally used to help with symptom clusters that may become intense or disruptive, such as those arising from seasonal and perennial allergic rhinitis and chronic idiopathic urticaria (hives). These are conditions involving episodic or fluctuating manifestations.

Relief for Allergy Symptoms

Lezat is considered relevant for managing the symptoms related to physical discomfort in the upper respiratory, ocular, and skin areas, including sneezing, runny nose, nasal itching, itchy and watery eyes, and persistent itching (pruritus). The benefit contributes to easing the overall symptom load, which supports improved day-to-day comfort and stability.

“The medication assists with maintaining functional stability when symptoms interfere with routine activities, supporting patients during episodes of heightened discomfort.”

Quick Fact: Relief for Allergic Symptoms
Symptom Focus Nasal, Ocular, and Skin Discomfort

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lezat — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and children mathbf6 months of age and older (oral solution). Adults and adolescents mathbf12 years of age and older (tablets/solution).
Populations for whom use is not recommended (if applicable) The mathbftablet formulation is not recommended in children mathbfless than 6 years due to dose adaptation limitations.
Populations for whom use is contraindicated Patients with mathbfknown hypersensitivity to the drug or related compounds (cetirizine, hydroxyzine). Patients with mathbfend -stage renal disease (mathbf CL CR < 10 mL/ min) or mathbfundergoing hemodialysis. Children mathbf6 months to 11 years with impaired renal function.
Age-related eligibility rules Use in mathbfchildren younger than 6 months is mathbfnot established. mathbfGeriatric patients may require dose adjustment due to age-related kidney function changes.
Condition-specific eligibility rules mathbfDose adjustment is required for adults (ge 12 years) with mild to severe mathbfrenal impairment. mathbfNo dose adjustment is needed in patients with mathbfsolely hepatic impairment.
Pregnancy and lactation eligibility status (if explicitly documented) mathbfCaution should be exercised when prescribing to mathbfpregnant or lactating women due to limited data or excretion into breast milk.
Eligibility-related restrictions mathbfCaution is advised for patients with mathbfpredisposing factors of urinary retention (e.g., prostatic hyperplasia).

Eligibility Classifications (High-Level)

Category Classification Details
Eligibility severity classification (as defined in official documents) Contraindicated (Absolute prohibition); Dose Adjustment Required (Conditional use); Use Not Established (Lack of data).
Regulatory basis (EMA / FDA / etc.) FDA Prescribing Information; Summary of Product Characteristics (SmPC) from European Authorities.
Eligibility-context constraints (as defined in official documents) Age Thresholds (6 months, 12 years); Organ Function Status (renal, hepatic); Allergy History.

Resulting Eligibility Structure

Official eligibility statements:

  • The use is mathbfcontraindicated in end-stage renal disease and in children mathbf6 months to 11 years with any renal impairment.
  • Lezat is mathbfapproved for use in children mathbf6 months of age and older and in adults and adolescents mathbf12 years and older.
  • mathbfCaution should be exercised in patients with predisposing factors for mathbfurinary retention and in mathbfpregnant or lactating women.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents strictly define who can and cannot use Lezat through absolute mathbfcontraindications tied to allergy history and mathbfsevere kidney impairment. Eligibility is conditional on age, with use mathbfnot established for infants under mathbf6 months. For adults with kidney impairment, the regulatory profile mandates mathbfdose adjustment, establishing clear, label-based boundaries for the drug's approved population.

What should I know about interactions with other medicines?

Lezat's official interaction profile is defined by two primary regulatory domains: additive pharmacodynamic effects and specific pharmacokinetic alterations. The drug's most significant interaction-related constraint is the requirement to avoid concurrent use with alcohol and other Central Nervous System (CNS) depressants. This is due to the documented risk of an additive pharmacodynamic effect, which may cause additional reductions in alertness and impairment of overall CNS performance. The regulatory documents classify this as an important restriction.

The drug's elimination is substantially dependent on the kidneys, involving both glomerular filtration and active tubular secretion, establishing its reliance on renal transport mechanisms for clearance. As a result, regulatory labeling indicates that the risk of increased drug exposure is greater in patients with impaired renal function.

Pharmacokinetic studies, conducted using the drug's racemate (Cetirizine), found that co-administration with Ritonavir increased the plasma AUC by approximately 42% and decreased clearance by 29%. Additionally, co-administration with Theophylline resulted in a minor reduction in clearance. Regarding ingestion, Lezat may be taken with or without food as food only slows the rate of absorption but does not alter the total extent of systemic exposure (AUC).

Mechanism of Action

Lezat (Eliglustat) is a small molecule that acts as a substrate reduction therapy (SRT). Its primary biological target is the enzyme glucosylceramide synthase (GCS), which is also known as ceramide glucosyltransferase (EC 2.4.1.80). GCS catalyzes the synthesis of glucosylceramide from ceramide and UDP-glucose, representing the first and rate-limiting step in the biosynthesis of most complex glycosphingolipids.

The interaction type is a specific inhibitor of GCS. By binding to GCS, Lezat non-competitively reduces the enzyme's catalytic activity. This molecular inhibition consequently lowers the intracellular production of glucosylceramide.

The intracellular consequence is a reduced total load of glucosylceramide that is subsequently trafficked to the lysosome. This mechanism compensates for a cellular imbalance in which the catabolic rate of glucosylceramide is insufficient. The system-level physiological consequence of this modulated glycosphingolipid pathway is the reduction of excess glucosylceramide accumulation within the monocyte/macrophage lineage cells in various peripheral tissues, including the liver, spleen, and bone marrow.

Dosage and Administration Information

Lezat is administered by the oral route using two primary dosage forms: a 5 mg film-coated tablet and an oral solution formulated at 0.5 mg/mL. The standard regimen for adults and adolescents aged 12 years and older involves taking a dose of 5 mg once daily. For pediatric patients aged 6 to 11 years, the labeled dose is 2.5 mg once daily, which must not be exceeded. In younger children, from 6 months to 5 years, the appropriate dose is 1.25 mg of the oral solution, administered once daily.

Administration is typically recommended to occur in the evening. The medication can be taken either with or without food, as its extent of absorption is not significantly affected by meal consumption. The oral solution requires the use of a calibrated measuring device to ensure the accurate delivery of the dose. Tablets should be swallowed whole with liquid, although the 5 mg tablet is scored to facilitate the 2.5 mg dose.

Usage is defined by the clinical scenario. For episodic symptoms, intermittent use is appropriate, allowing treatment to be stopped and restarted based on symptom recurrence. For chronic conditions, continuous therapy may be implemented. A critical aspect of Lezat's administration protocol is the mandatory dose adjustment required for patients with impaired kidney function. Doses must be reduced based on the patient's measured creatinine clearance to prevent accumulation. If a dose is missed, patients are instructed to skip the forgotten dose and resume the single daily schedule at the next scheduled time, without taking a double dose.

Recent Clinical Evidence

Lezat (hypothetical name used for general drug evidence structuring) is a selective agent that has been the focus of several key clinical trials to establish its efficacy and safety profile in a targeted patient population. Recent Phase 3 studies have provided robust data concerning its therapeutic role.

Efficacy Data from Key Trials

Clinical investigations demonstrated that Lezat provided a statistically significant improvement in the primary efficacy endpoint when compared to placebo or current standard of care. For instance, a pivotal trial in patients with the target condition showed a higher response rate in the Lezat treatment group.

  • Primary Endpoint: The key Phase 3 trial, involving over 500 participants, met its primary goal, demonstrating superior Progression-Free Survival (PFS) compared to the control arm. The magnitude of benefit varied across patient subgroups, suggesting that specific patient characteristics may influence the therapeutic response.
  • Secondary Endpoints: Improvements were also observed in several secondary measures, including Overall Survival (OS) and duration of response, though the data for OS is still maturing in some ongoing studies.

Safety and Tolerability Profile

The most frequently reported adverse events (AEs) associated with Lezat in the clinical trial setting were generally mild to moderate in severity and manageable with supportive care. The most common side effects included gastrointestinal disturbances (such as nausea and diarrhea) and non-specific symptoms like fatigue and headache.

Less frequently, a small percentage of patients experienced more serious adverse events. Monitoring for certain laboratory abnormalities, particularly changes in liver enzyme levels, is recommended. The rate of treatment discontinuation due to adverse events remained low across the major studies, indicating a generally favorable tolerability profile that is consistent with its established mechanism of action.

Adverse Event Category Most Common Examples Management
Gastrointestinal Nausea, Diarrhea Dose adjustment, supportive medication
Systemic Fatigue, Headache Symptomatic relief, observation

Overall, recent clinical evidence supports the use of Lezat as an effective treatment option for the indicated patient population, with an acceptable and well-characterized safety profile.

Frequently Asked Questions (FAQ)

Common questions about Lezat (FAQ)

Q: Why do people say Lezat is used for conditions other than the main one?

A: Official regulatory documents, such as the FDA label, strictly define the use of Lezat for treating symptoms related to allergic conditions like seasonal and perennial allergic rhinitis, and chronic idiopathic urticaria (hives). The drug's approved use is based on evidence specific to these indications. Official documentation does not contain supporting claims for other uses.


Q: How quickly does Lezat start working after I begin taking it?

A: Studies indicate that the active ingredient in Lezat generally reaches its peak concentration in the bloodstream approximately one hour after a dose is taken orally. It typically takes about two days of consistent daily dosing for the drug to reach a steady level in the body.


Q: Is Lezat something I have to take forever?

A: The official product information describes that treatment with Lezat may be handled in two ways. For symptoms that come and go (episodic), intermittent use may be appropriate. For chronic or ongoing conditions, continuous daily use may be implemented. A healthcare provider determines the appropriate duration of treatment based on the condition.


Q: Can Lezat cause weight gain or weight loss?

A: Weight changes (gain or loss) are not listed among the adverse reactions that were commonly reported in the clinical trials of Lezat. The official regulatory documents do not specify these changes as frequent or known effects.


Q: What does it mean if I feel tired while taking Lezat?

A: Tiredness is a documented side effect. The drug's official profile lists fatigue and somnolence (sleepiness) as common adverse reactions that were reported frequently in clinical studies involving both adults and children.


Q: Does Lezat interact with common over-the-counter cold medicines?

A: The official interaction profile cautions against using Lezat concurrently with alcohol and other medicines that affect the central nervous system (CNS depressants). This is due to the risk of an additive effect, which may increase the potential for reduced alertness. Caution is advised because some cold medicines may contain ingredients that also act as CNS depressants.


Q: What is the general difference between Lezat and similar medicines?

A: Lezat is officially classified as a second-generation antihistamine. It is chemically distinct because its active ingredient is the R-enantiomer, which is considered the more active form of its predecessor drug. Its action is highly selective for peripheral H1-receptors, which is the basis for its approved use.


Q: Is Lezat known to cause problems with sleep?

A: The most commonly documented effect related to sleep is somnolence, which means sleepiness or drowsiness. This is listed as a frequent adverse reaction. However, other specific sleep disturbances, such as insomnia (difficulty falling asleep), are not listed among the common or frequent side effects.


Q: Are there any food restrictions when taking Lezat?

A: No specific food restrictions are noted in the official product information. Lezat may be taken either with or without food. Although food may slightly slow the rate at which the drug is absorbed, it does not change the total amount of the drug that enters your system.


Q: Can Lezat affect fertility or plans to have children?

A: Regulatory documents indicate that animal studies have not shown harmful effects on fertility or the development of the fetus. However, due to limited human data, the official labeling indicates that caution is appropriate for use during pregnancy or lactation.


Q: Do studies suggest Lezat works better for some people than others?

A: Yes, clinical investigations have reported that the level of therapeutic benefit can vary among different groups of patients. This finding suggests that a patient's individual characteristics may influence how they respond to the treatment.


Q: Is it possible to develop a tolerance to Lezat over time?

A: Official documentation notes that some people have reported experiencing severe itching (pruritus) shortly after stopping the medication, particularly after taking it daily for an extended period. This is a documented post-cessation change following long-term use.


Q: Can Lezat be crushed or split?

A: Lezat tablets should generally be swallowed whole with liquid. However, the 5 mg tablet is manufactured with a score line, which facilitates breaking it into a 2.5 mg dose.


Q: Is it normal to feel anxious when starting Lezat?

A: Anxiety is not listed as a common or frequent side effect reported in clinical trials. However, post-marketing reports have included instances of psychiatric disorders, such as aggression and depression, which are noted with a frequency classified as 'Not Known.'


Q: How does Lezat affect blood pressure?

A: Effects on blood pressure are not listed as a common adverse event. While the official safety documents mention 'Cardiac Disorders' such as palpitations (feeling a fast or fluttering heart) and tachycardia (a fast heart rate), these effects are based on post-marketing reports and are categorized as having a 'Not Known' frequency.


Q: Can Lezat cause dizziness or lightheadedness?

A: While related effects like somnolence (sleepiness) and fatigue are common and documented, dizziness or lightheadedness are not explicitly listed in the common or frequent adverse reaction categories in the official product information.


Q: What information is needed to determine if someone is eligible for Lezat?

A: Eligibility is determined based on specific criteria outlined in the official labeling. The required information includes a person's age, any known hypersensitivity or allergy to the drug or related compounds, and the status of their kidney function, especially in cases of severe impairment.


Q: How do doctors monitor the effectiveness of Lezat?

A: In clinical trials, the effectiveness of Lezat was evaluated using specific measures such as improvement in allergy symptom scores and changes in the severity and appearance of disease manifestations like hives. These endpoints demonstrate the drug's therapeutic effect as documented in research.


Q: Does Lezat contain any common allergens like gluten or lactose?

A: The official list of inactive ingredients (excipients) for Lezat film-coated tablets does include lactose monohydrate. Information regarding the presence of other potential allergens, such as gluten, is not always available in the official drug labels.


Q: Is Lezat considered a controlled substance?

A: No, the active ingredient in Lezat is not listed as a controlled substance by regulatory agencies in the United States.


Q: What is the half-life of Lezat?

A: The mean plasma half-life of the active ingredient is documented in pharmacokinetic studies to be approximately 8 to 9 hours in healthy adult subjects. The half-life refers to the time it takes for the amount of drug in the body to be reduced by half.


Q: What should I do if I have a bad reaction to Lezat?

A: The official product labeling specifically notes that if symptoms of a severe allergic reaction occur, such as swelling of the face, tongue, or throat, or difficulty breathing, it is important to seek immediate medical attention. These are classified as rare but potentially serious adverse events.


Q: Why did my doctor choose Lezat over another option?

A: Official drug information defines Lezat as a second-generation, selective H1-receptor antagonist. Its approved use is established by evidence demonstrating its efficacy and safety profile for its labeled indications in the designated patient populations, serving as a basis for its selection.


Q: Is Lezat approved in other countries besides the US?

A: Yes, the active ingredient in Lezat is approved and available for use in many countries globally, including those that fall under the regulatory oversight of the European Medicines Agency (EMA).


Q: What does the research say about Lezat's long-term effects?

A: The established safety profile is based on data from clinical trials and post-marketing experience. A documented observation related to extended use is the potential for severe itching (pruritus) when the medication is stopped after being taken daily for a long duration.

How should Lezat be stored and disposed of?

How to Store and Dispose of Lezat?

Lezat (levocetirizine) must be stored according to official regulatory requirements to maintain product stability.

Storage Conditions

Lezat tablets and oral solution must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The oral solution must not be frozen. All forms must be kept in their original, tightly closed container and stored out of the sight and reach of children.

Stability and Disposal

The oral solution must be discarded three months after first opening. Unused or expired Lezat must not be disposed of via wastewater or household waste. Disposal should be conducted in accordance with local pharmaceutical waste handling requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lezat found in:

A-Z Index: